Company Overview - Tango Therapeutics, Inc. (TNGX) shares increased by 7.5% to close at $5.16, with notable trading volume compared to typical sessions, and a total gain of 157.4% over the past four weeks [1][2] Pipeline Developments - The company recently dosed the first patient in the TNG456 phase I/II study targeting MTAP-deleted solid tumors, particularly glioblastoma, which has contributed to positive market sentiment regarding its pipeline of precision cancer medicines [2] Financial Expectations - Tango Therapeutics is projected to report a quarterly loss of $0.36 per share, reflecting a year-over-year decline of 50%, with expected revenues of $5.79 million, down 70.9% from the previous year [3] - The consensus EPS estimate for the quarter has been revised slightly higher in the last 30 days, indicating a potential for price appreciation if the trend continues [4] Industry Context - Tango Therapeutics operates within the Zacks Medical - Biomedical and Genetics industry, where it holds a Zacks Rank of 3 (Hold) [5] - Another company in the same industry, Protagonist Therapeutics (PTGX), experienced a 1.1% decline in its stock price, with a monthly return of 17.5% [5][6]

Group 1 - U.S. stock futures are higher, with Dow futures gaining over 150 points [1] - Sarepta Therapeutics, Inc. shares fell 31.4% to $24.86 after suspending ELEVIDYS shipments and pausing ENVISION trial due to a second fatal liver failure in non-ambulatory Duchenne patients [1] Group 2 - KULR Technology Group, Inc. shares fell 21.9% to $0.8980 following a 1-for-8 reverse stock split [4] - Gold Royalty Corp. shares dipped 14.7% to $1.95, despite Canaccord Genuity initiating a Buy rating with a $3 price target [4] - Solid Biosciences Inc. shares fell 8% to $4.15, with JMP Securities reiterating a Market Outperform rating and maintaining a $15 price target [4] - Omada Health, Inc. shares declined 5.4% to $16.18 [4] - Repligen Corporation shares decreased 4% to $122.50 [4] - IonQ, Inc. shares slipped 3.2% to $36.65 [4] - Tango Therapeutics, Inc. shares declined 3.2% to $4.54 [4]

Summary of Tango Therapeutics Conference Call Company Overview - **Company**: Tango Therapeutics - **Industry**: Biotechnology, specifically focused on oncology and synthetic lethality Core Insights and Arguments - **Synthetic Lethality Platform**: Tango's discovery platform is based on synthetic lethality, which targets tumor suppressor gene loss that cannot be directly targeted due to their inactivation. This approach supplements existing therapies that focus on activated oncogenes [2][3] - **Pipeline Development**: Tango is advancing its lead asset, TNG-462, a PRMT5 inhibitor, which is synthetic lethal with MTAP deletions, common in lung and pancreatic cancers. The company is nearing the end of a Phase III study for this asset [8][9] - **Durability of Treatment**: The efficacy of TNG-462 is highlighted by its durability in patients, with some remaining on treatment for over a year, which is notable compared to standard chemotherapy options [10][11] - **Tolerability Profile**: TNG-462 is reported to have a best-in-class tolerability profile, making it suitable for patients with difficult-to-treat cancers [12] Pipeline Details - **TNG-462**: Focused on pancreatic and lung cancers, with plans to present data from over 20 patients in each category later this year [10] - **TNG-456**: A next-generation brain-penetrant asset aimed at glioblastoma, which has a high prevalence of MTAP deletions. This asset is expected to deliver more drug into the brain due to increased selectivity [13][15] - **TNG-260**: A coREST inhibitor targeting STK11 mutation patients, which represents a significant opportunity in non-small cell lung cancer. The program is currently in dose expansion [30][31] Competitive Landscape - **Key Competitors**: The primary competitors identified are Bristol Myers Squibb (BMS) and Amgen, with Tango believing it has a competitive edge in terms of pharmacokinetics (PK) and tolerability [21][22] - **Market Positioning**: Tango positions itself as a leader in the PRMT5 space, with a significant lead over other companies like AstraZeneca and BeiGene [22] Combination Strategies - **Combination with RAS Mutations**: Tango is initiating a study combining TNG-462 with RAS mutation-targeted therapies, which is expected to be transformative for pancreatic and lung cancer patients [27] - **Focus on Tolerability**: The company is monitoring overlapping toxicities in combination therapies but expects good tolerability based on existing safety profiles [29] Financial and Strategic Focus - **Capital Allocation**: Tango's capital allocation strategy is heavily focused on advancing the development of TNG-462 for pancreatic cancer, with plans to start a pivotal study next year [38] - **Investor Perception**: There is a belief that investors have underestimated the importance of PRMT5 as a target and Tango's position in the market. The company asserts it is well-resourced to compete effectively [36][37] Additional Insights - **Innovative Approach**: Tango's approach to synthetic lethality and its focus on specific genetic mutations (like STK11 and MTAP) are seen as innovative and potentially game-changing in oncology [30][31] - **Clinical Proof of Concept**: The company has demonstrated that its findings in animal models translate to human patients, reinforcing the validity of its therapeutic strategies [32][34]

Company Overview - Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering novel drug targets and advancing precision medicine for cancer treatment [3] - The company employs the genetic principle of synthetic lethality to develop therapies targeting critical cancer-related pathways [3] Upcoming Event - Barbara Weber, M.D., President and CEO of Tango Therapeutics, will participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference on June 10, 2025, from 3:20 to 3:55 PM ET [1] - The event will be available via live webcast on the company's website, with a replay accessible for 90 days post-presentation [2]

Core Insights - Tango Therapeutics has initiated the dosing of the first patient in the TNG456 Phase 1/2 trial targeting MTAP-deleted solid tumors, particularly glioblastoma (GBM) [1][2] - TNG456 is a next-generation PRMT5 inhibitor designed to penetrate the brain and is expected to offer a new treatment option for patients with GBM, where current survival rates are below 10% [2] - The trial aims to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of TNG456 both as a monotherapy and in combination with abemaciclib [2] Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on discovering novel drug targets and developing precision cancer medicines [3] - The company employs the genetic principle of synthetic lethality to create therapies aimed at critical cancer targets [3]

Company Performance - Tango Therapeutics reported a quarterly loss of $0.36 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.34, and compared to a loss of $0.35 per share a year ago, indicating an earnings surprise of -5.88% [1] - The company posted revenues of $5.39 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 13.94%, and down from $6.47 million in the same quarter last year [2] - Over the last four quarters, Tango Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - Tango Therapeutics shares have declined approximately 63.1% since the beginning of the year, contrasting with the S&P 500's decline of -3.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.34 on revenues of $5.72 million, and for the current fiscal year, it is -$1.37 on revenues of $28.53 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Tango Therapeutics belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% of ranked industries [8] - The performance of Tango Therapeutics may be influenced by the overall industry outlook, as empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions [5][8]

[Business Highlights and Pipeline Update](index=1&type=section&id=Business%20Highlights%20and%20Pipeline%20Update) Tango Therapeutics advanced its clinical pipeline, notably TNG462, and extended its cash runway through strategic resource allocation - The company has extended its cash runway into the **first quarter of 2027** by reducing preclinical pipeline spending, target discovery efforts, and deferring certain clinical combination studies[1](index=1&type=chunk)[2](index=2&type=chunk)[11](index=11&type=chunk) - Presented five posters at the 2025 American Association for Cancer Research (AACR) Annual Meeting, highlighting preclinical data from PRMT5 programs (TNG462, TNG456) and the HBSL1 molecular glue degrader (TNG961)[7](index=7&type=chunk)[9](index=9&type=chunk) [TNG462 (MTA-cooperative PRMT5 inhibitor)](index=1&type=section&id=TNG462%20(MTA-cooperative%20PRMT5%20inhibitor)) TNG462, a PRMT5 inhibitor, is progressing with a data update expected in 2H 2025 and a combination trial starting in Q2 2025 - A clinical data update for the TNG462 Phase 1/2 monotherapy trial is expected in the **second half of 2025**, focusing on efficacy, safety, and tolerability in pancreatic and lung cancer[1](index=1&type=chunk)[2](index=2&type=chunk)[3](index=3&type=chunk) - A combination trial of TNG462 with Revolution Medicines' RAS(ON) inhibitors (daraxonrasib and zoldonrasib) is on track to begin enrollment in **Q2 2025**[1](index=1&type=chunk)[2](index=2&type=chunk)[4](index=4&type=chunk) - The company aims to initiate a TNG462 monotherapy registrational study in pancreatic cancer in **2026**[2](index=2&type=chunk)[3](index=3&type=chunk) [Other Pipeline Programs](index=2&type=section&id=Other%20Pipeline%20Programs) Tango Therapeutics is advancing TNG456, TNG260, and TNG961, with clinical updates and trial initiations expected for these programs - **TNG456 (Glioblastoma):** A Phase 1/2 clinical trial is planned to begin enrolling in **Q2 2025** for patients with MTAP-deleted solid tumors, with a focus on glioblastoma[5](index=5&type=chunk)[8](index=8&type=chunk) - **TNG260 (CoREST inhibitor):** Proof-of-mechanism has been established. A clinical update on the combination study with pembrolizumab in STK11-mutant NSCLC is expected in **2H 2025**[5](index=5&type=chunk)[8](index=8&type=chunk) - **TNG961 (HBS1L degrader):** Identified as a development candidate for FOCAD-deleted solid tumors, which occur in **20-40%** of MTAP-deleted cancers. Preclinical models show tumor regression[6](index=6&type=chunk)[8](index=8&type=chunk) [Upcoming Milestones](index=3&type=section&id=Upcoming%20Milestones) Key clinical milestones for 2025 include data updates for TNG462 and TNG260, and trial initiations for TNG456 and TNG462 combination - **2Q 2025:** Begin enrollment for TNG456 Phase 1/2 trial - **2Q 2025:** Begin enrollment for TNG462 + RAS(ON) inhibitors combination trial - **2H 2025:** Provide TNG462 Phase 1/2 clinical data update - **2H 2025:** Provide TNG260 clinical data update[15](index=15&type=chunk) [Financial Results](index=3&type=section&id=Financial%20Results) Tango Therapeutics reported Q1 2025 financial results, including collaboration revenue, net loss, and a strong cash position extending into Q1 2027 [Financial Performance (Q1 2025)](index=3&type=section&id=Financial%20Performance%20(Q1%202025)) Q1 2025 saw a decrease in collaboration revenue and R&D expenses, alongside an increase in G&A, leading to a net loss Consolidated Statements of Operations (in thousands, except per share data) | Metric | Q1 2025 (in thousands) | Q1 2024 (in thousands) | | :--- | :--- | :--- | | Collaboration Revenue | $5,392 | $6,471 | | Research and Development | $36,442 | $38,065 | | General and Administrative | $11,480 | $10,661 | | Loss from Operations | ($42,530) | ($42,255) | | **Net Loss** | **($39,876)** | **($37,914)** | | **Net Loss Per Share** | **($0.36/share)** | **($0.35/share)** | - The decrease in R&D expenses was driven by discontinued clinical programs (TNG908 and TNG348), partially offset by increased spending on TNG961 and TNG456[13](index=13&type=chunk) [Financial Position and Cash Runway](index=3&type=section&id=Financial%20Position%20and%20Cash%20Runway) Tango's cash, cash equivalents, and marketable securities totaled $216.7 million as of March 31, 2025, extending its cash runway into Q1 2027 - Cash, cash equivalents, and marketable securities totaled **$216.7 million** as of **March 31, 2025**[11](index=11&type=chunk) - The company's cash runway is now expected to be sufficient to fund operations into the **first quarter of 2027**[1](index=1&type=chunk)[11](index=11&type=chunk) Consolidated Balance Sheet Highlights (in thousands) | Metric | March 31, 2025 (in thousands) | December 31, 2024 (in thousands) | | :--- | :--- | :--- | | Cash and cash equivalents | $58,432 | $69,530 | | Marketable securities | $158,292 | $188,387 | | **Total Assets** | **$274,306** | **$316,492** | | Total Liabilities | $107,550 | $116,975 | | Total Stockholders' Equity | $166,756 | $199,517 |

Core Insights - Tango Therapeutics is advancing its clinical-stage pipeline, particularly focusing on TNG462, a PRMT5 inhibitor, with data updates expected in the second half of 2025 [1][6][16] - The company has a strong cash position of $217 million as of March 31, 2025, which is projected to fund operations into the first quarter of 2027 [1][9] - The company is strategically reducing preclinical spending to extend its cash runway while prioritizing its PRMT5 programs [2][9] Pipeline Update - TNG462 is anticipated to show promising efficacy, safety, and tolerability data, particularly in pancreatic and lung cancer, with a registrational study planned for next year [2][6] - TNG456, a next-generation PRMT5 inhibitor, is set to begin a Phase 1/2 trial for glioblastoma in the second quarter of 2025 [4][6] - TNG260 is undergoing a Phase 1/2 trial in combination with pembrolizumab for NSCLC, with updates expected in the second half of 2025 [5][6] Financial Results - Collaboration revenue for the first quarter of 2025 was $5.4 million, down from $6.5 million in the same period of 2024 [10] - Research and development expenses decreased to $36.4 million in Q1 2025 from $38.1 million in Q1 2024, attributed to reduced spending on discontinued programs [11] - The net loss for the first quarter of 2025 was $39.9 million, or $0.36 per share, compared to a net loss of $37.9 million, or $0.35 per share, in Q1 2024 [12][20] Upcoming Milestones - Clinical data updates for TNG462 and TNG260 are expected in the second half of 2025 [16] - Enrollment for the combination trial of TNG462 with RAS(ON) inhibitors is projected to begin in the second quarter of 2025 [1][16]

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $1.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -11.71%. A quarter ago, it was expected that this company would post a loss of $1.10 per share when it actually produced a loss of $1.09, delivering a surprise of 0.91%.Over the last four quarters, the company has s ...

Company Overview - Tango Therapeutics, Inc. (TNGX) is expected to report a quarterly loss of $0.34 per share, reflecting a year-over-year change of +2.9% [3] - Revenues are anticipated to be $6.27 million, which is a decrease of 3.1% from the same quarter last year [3] Earnings Expectations - Wall Street anticipates a year-over-year increase in earnings despite lower revenues, with the earnings report set to be released on May 12 [1][2] - The consensus EPS estimate has been revised 1.52% lower over the last 30 days, indicating a bearish sentiment among analysts [4][10] Earnings Surprise Prediction - The Most Accurate Estimate for Tango Therapeutics is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -2.19% [10][11] - The company currently holds a Zacks Rank of 4, which complicates the prediction of an earnings beat [11] Historical Performance - In the last reported quarter, Tango Therapeutics was expected to post a loss of $0.32 per share but actually reported a loss of $0.35, resulting in a surprise of -9.38% [12] - Over the past four quarters, the company has beaten consensus EPS estimates two times [13] Industry Comparison - Mirum Pharmaceuticals, Inc. (MIRM), another player in the Zacks Medical - Biomedical and Genetics industry, is expected to post a loss of $0.39 per share, indicating a year-over-year change of +27.8% [17] - Mirum's revenues are projected to be $98.47 million, up 42.3% from the previous year [17] - Despite a recent EPS estimate revision of 2.8% downwards, Mirum has a Zacks Rank of 2 (Buy) but an Earnings ESP of -4.27% [18]